Josh Riggs Acquires 3,390 Shares of OncoCyte Co. (NASDAQ:OCX) Stock

OncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs purchased 3,390 shares of OncoCyte stock in a transaction dated Thursday, April 11th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $10,000.50. Following the completion of the purchase, the chief executive officer now directly owns 3,505 shares in the company, valued at approximately $10,339.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

OncoCyte Stock Up 8.7 %

Shares of OCX opened at $2.75 on Wednesday. OncoCyte Co. has a fifty-two week low of $2.08 and a fifty-two week high of $6.80. The firm’s 50 day moving average price is $2.96 and its 200 day moving average price is $3.06.

Institutional Investors Weigh In On OncoCyte

Several large investors have recently added to or reduced their stakes in OCX. Vanguard Group Inc. increased its position in shares of OncoCyte by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,986,270 shares of the company’s stock valued at $5,940,000 after purchasing an additional 90,534 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of OncoCyte in the 2nd quarter valued at approximately $896,000. Goldman Sachs Group Inc. increased its position in shares of OncoCyte by 5.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 460,004 shares of the company’s stock valued at $686,000 after purchasing an additional 24,964 shares during the last quarter. Geode Capital Management LLC increased its position in shares of OncoCyte by 23.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,228,553 shares of the company’s stock valued at $283,000 after purchasing an additional 236,099 shares during the last quarter. Finally, LPL Financial LLC increased its position in shares of OncoCyte by 58.1% in the 2nd quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock valued at $98,000 after purchasing an additional 40,000 shares during the last quarter. 55.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Benchmark reissued a “speculative buy” rating and issued a $5.00 price target on shares of OncoCyte in a research note on Monday. StockNews.com started coverage on shares of OncoCyte in a research note on Friday, April 12th. They set a “sell” rating on the stock.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.